| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | 0 | 36.054 | 120.444 | 660.255 |
| Total Income - EUR | - | - | - | - | - | - | 239 | 118.794 | 130.934 | 743.466 |
| Total Expenses - EUR | - | - | - | - | - | - | 20.340 | 78.075 | 127.962 | 719.272 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | -20.101 | 40.718 | 2.972 | 24.194 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | -20.101 | 40.357 | 1.767 | 4.107 |
| Employees | - | - | - | - | - | - | 0 | 1 | 2 | 7 |
Check the financial reports for the company - Bio-Mar R&D S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | 116.988 | 116.876 | 137.653 | 276.478 |
| Current Assets | - | - | - | - | - | - | 20.810 | 201.540 | 270.890 | 201.231 |
| Inventories | - | - | - | - | - | - | 978 | 155.961 | 235.876 | 148.758 |
| Receivables | - | - | - | - | - | - | 17.286 | 31.523 | 21.629 | 19.141 |
| Cash | - | - | - | - | - | - | 2.546 | 14.056 | 13.385 | 33.332 |
| Shareholders Funds | - | - | - | - | - | - | -20.061 | 20.066 | 21.739 | 25.650 |
| Social Capital | - | - | - | - | - | - | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | - | 157.859 | 298.350 | 386.804 | 452.058 |
| Income in Advance | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "1101 - 1101" | |||||||||
| CAEN Financial Year |
1092
|
|||||||||
Comments - Bio-Mar R&D S.r.l.